Akebia (AKBA) Therapeutics announced multiple positive business updates. As of January, Vafseo tablets are available in the U.S. for adult patients with anemia due to chronic kidney disease on ...
Hosted on MSN1mon
The Climbing Type Of Plant That Can Make Your Backyard A Cozy OasisOther vines, like Akebia (Akebia quinata ... there's an array of vining plants you can use to create a screen for privacy or shade. When choosing perennials, consider which USDA growing zone ...
$240,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "H.R. 4366, Consolidated ...
The FDA, which turned away Akebia's initial application last March 2022, has a target action of Wednesday on the company's resubmission, which included Explore Our Brands WSJ ...
NASDAQ AKBA opened at $2.38 on Thursday. Akebia Therapeutics has a 12 month low of $0.80 and a 12 month high of $2.48. The stock’s 50 day moving average is $1.95 and its 200 day moving average ...
On Wednesday, H.C. Wainwright analysts maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA). The firm's endorsement follows Akebia's announcement on January 13 that the U.S. commercial ...
On Tuesday, H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) stock with a steady price target of $7.50, significantly above the current trading price of $1.88.
New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S. Akebia Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results